May. 13 at 12:51 PM
$KURA i remain confident and bullish in this team, bic menin inhibitor and pipeline fti asset. my updated thesis is below.
fdmc:
$1B (at
$9.50/sh)
cash:
$575M as of March 2026.
catalysts: 1H 2026 Updated Phase 1b data for ziftomenib + 7+3 intensive chemotherapy in frontline AML (KOMET-007) and Preliminary data for darlifarnib + adagrasib in KRAS G12C-mutated solid tumors.
Executive Summary
--Commercial Status: Kura Oncology is now a revenue-generating entity following the first full quarter of KOMZIFTI (ziftomenib) sales.
--Lead Indication: Approved for R/R NPM1-mutant AML; early launch data shows 85 new patient starts and 157 total prescriptions, indicating strong repeat use.
--Mechanism of Action: The drug works by specialized inhibition of the menin-NPM1 protein-protein interaction, reversing the block on cellular differentiation that drives leukemogenesis.
--Market Expansion: Beyond its current R/R NPM1 label, Kura is aggressively pursuing the frontline AML market (
$7B+ opportunity) with its Phase 3 KOMET-017 trial now enrolling.
--Financial Foundation: Backed by a strategic
$580.8M cash position and a 50/50 U.S. profit-share partnership with Kyowa Kirin, Kura is funded through pivotal frontline readouts in 2028.
Financials & Capital Structure (as of Dec 31, 2025)
--Fully Diluted Share Count: 107,642,636 shares (conservative "maximum dilution" model, including ~88.7M common shares outstanding and ~18.8M shares reserved for the Equity Incentive Plan (both allocated and unallocated) to reflect the total potential share overhang as the company scales).
--Fully Diluted Market Cap: ~
$1.02B (at
$9.52/share).
--Cash Position:
$575M (as of Mar 2026).
--Enterprise Value (EV): ~
$460M; notable undervaluation despite missing Q1 revenue consensus.
--Cash Runway: Sufficient to fund operations through topline Phase 3 results in 2028, supported by
$180M in anticipated milestone payments.
Pipeline and Mechanism of Action (MOA)
--Komzifti (ziftomenib) - Menin Inhibitor: Blocks menin interaction with KMT2A/NPM1. Status: Approved for R/R NPM1-m AML; Phase 3 KOMET-017 for frontline AML.
--Darlifarnib (KO-2806) - Next-Gen FTI: Inhibits farnesyl transferase (RHEB/HRAS). Status: Phase 1 combinations in RCC and KRAS-mutant solid tumors.
--KO-7246: Next-gen menin inhibitor exploring large-market indications like diabetes and cardiometabolic diseases.
Catalyst Readout Timeline
--1H 2026: EHA 2026 Frontline Data: Updated 96% CRc results in an Oral Presentation (June 2026).
--1H 2026: Preliminary data for darlifarnib + adagrasib in KRAS G12C-mutated solid tumors (ASCO 2026).
--2H 2026: Preliminary Phase 1 data for ziftomenib + gilteritinib in R/R NPM1/FLT3 co-mutated AML (KOMET-008).
--2028: Topline results and potential accelerated FDA review for frontline intensive chemotherapy AML (KOMET-017).
--2H 2026: Updated Phase 1a data for darlifarnib + cabozantinib in Renal Cell Carcinoma (RCC).
Competition and Competitive Positioning
--Commercial Momentum: Achieved >93% payer coverage in one full quarter, including Preferred Status on CVS Caremark and UnitedHealthcare formularies.
--The "Switching" Advantage: Management explicitly reported instances of patients switching from competing menin inhibitors (Syndax's Revuforj) to ziftomenib.
--Safety/Dosing Advantage: Once-daily oral tablet with no Boxed Warning for QTc, making it the superior choice for community oncology where monitoring is a burden.
Exec Team & BOD
--Troy E. Wilson, Ph.D., J.D. (CEO & Chairman): Co-founder of Kura Oncology; formerly co-founder, President, and CEO of Avidity Biosciences (acquired by Novartis for
$12B in 2026). Also co-founded Intellikine (acquired by Takeda) and Ambrx (acquired by J&J).
--Mollie Leoni, M.D. (CMO): Significant experience in oncology drug development, formerly at Celgene and Immunomedics.
--Brian Powl (CCO): Deep commercial expertise from Celgene (Abraxane/Revlimid) and Novartis.
--Kathleen Ford (COO): Extensive experience in clinical operations and drug development; formerly at Merck and GlaxoSmithKline.
Board of Directors
--Troy E. Wilson, Ph.D., J.D.: Chairman of the Board.
--Faheem Hasnain: Lead Independent Director; Chairman of Gossamer Bio and former CEO of Receptos.
--Carol A. Schafer: Chairperson of the Audit Committee; former Vice Chair of Equity Capital Markets at Wells Fargo Securities.
--Thomas Malley: Independent Director; President of Mossrock Capital and former portfolio manager at Janus.
--Mary Szela: Independent Director; CEO of TriSalus Life Sciences and former CEO of Arixa Pharmaceuticals.
--Helen Collins, M.D.: Independent Director; former CMO of Five Prime Therapeutics.
--Diane Parks: Independent Director; former Head of Commercial at Kite Pharma.
--Michael Vasconcelles, M.D.: Independent Director; Senior Advisor at Frazier Healthcare Partners and former Head of Oncology at Takeda/Millennium.
Bull Thesis
--Safety Profile is King: If Ziftomenib becomes the "cleaner" menin inhibitor (no QTc issues), it will likely capture the majority of the
$7B frontline AML market as doctors prioritize safety in elderly populations.
--Real-World Reliability: Total prescriptions (157) grew faster than new starts (85), proving high tolerability and refill velocity in the R/R population.
--Payer Dominance: Rapid 93% coverage significantly reduces friction for the much larger frontline launch, essentially "pre-clearing" the market.
--Frontline Superiority: Exceptional 96% CRc and centralized NGS MRD negativity (>80%) establish ziftomenib + 7+3 as the definitive backbone standard of care.
--Valuation Disconnect: At a sub-
$500M EV, the market is pricing Kura as a "failed launch" rather than a commercial-stage leader with a massive frontline catalyst in 2028.
--Platform Synergy: Darlifarnib's "resistance breaker" mechanism could extend the patent and commercial life of ziftomenib through proprietary combinations.
--Strategic Backing: The Kyowa Kirin partnership validates the asset and provides 50/50 profit sharing in the U.S. while offloading significant ex-U.S. commercialization costs.
Bear Thesis
--Second-Mover Disadvantage: Syndax may entrench itself in academic centers before Kura can fully ramp up, making it difficult to displace the established standard of care.
--Revenue Ramp Concerns: The
$5.8M product revenue missed consensus, fueling fears that "Preferred Status" isn't driving an immediate vertical sales spike.
--High Burn Rate: R&D and SG&A expenses rose significantly as Phase 3 KOMET-017 enrollment scales.
--Label Limitations: Until the frontline label is secured, Kura is confined to the small R/R NPM1 market, which may limit near-term revenue growth.
--Commercial Execution: As a first-time commercial launcher, Kura may struggle with the administrative complexities of a dual launch with Kyowa Kirin.
--Platform Failure: Failure in the upcoming KRAS/adagrasib readout would relegate Kura to a single-indication heme-oncology company.
--Financing Needs: Despite a strong cash balance, the high burn rate of Phase 3 trials and commercial launch may require dilutive capital raises before reaching profitability.
